Stem Cell Therapy Development Service for T1DM

Stem Cell Therapy Development Service for T1DM

The destruction of insulin-producing β-cells is the main pathophysiological feature of T1DM. As the prevalence of diabetes continues to grow, the race to find a cure is intensifying. Ace Therapeutics provides a complete set of stem cell therapy development service for research T1DM.

Stem Cells Therapy in The Treatment of T1DM

Stem cells open up a wide spectrum of diabetes research possibilities. Stem cell therapy using islet-like insulin-producing cells derived from human pluripotent stem cells has the potential to allow patients with T1DM to withdraw from insulin therapy. Furthermore, autologous transplantation using induced pluripotent stem cells-derived islet cells is expected to have the potential to treat T1DM patients without requiring immunosuppressive therapy.

Human Pluripotent Stem Cells Derived Pancreatic IsletsHuman Pluripotent Stem Cells Derived Pancreatic Islets (Ryota, I., et al. Cells, 2021.)

Our Services

With years of experience in stem cell therapy development, Ace Therapeutics is able to provide research service to generate islet-like cells through induced pluripotent stem cell (iPSC) technology. Our services include but not limited to the followings.

Our Services

Stem Cell Reprogramming

Sendai virus (RNA virus) based reprogramming can be used to reprogram a wide range of cell types and origins. The reprogramming process is based on transfection of transcriptional factor genes (Oct4, Sox2, c-Myc and Klf4).

Stem Cell Culture

We offer a serum-free medium for induced pluripotent stem cells that maintain pluripotency, trilineage differentiation potential and karyotypic stability.

Stem Cell Engineering

Using lipid-base transfection, electroporation, viral approaches or genome engineering tools such as CRISPR or TALEN.

Stem Cell Differentiation

Using consecutive cytokines or signaling modulators to control the differentiation of iPSCs into pancreatic β-cells. Identifying the proliferative signals as well as instructive signals that induce the differentiation process.

Stem Cell Characterization

Includes assessing pluripotency, genomic stability, and safety. And the safety assays include sterility, mycoplasma, endotoxin, and adventitious viral testing.

Features of Our Services

Highly CustomizableHighly Customizable

One-stop ServicesOne-stop Services

High QualityHigh Quality

Professional TeamProfessional Team

Ace Therapeutics offers cost-effect and high-quality research services related to T1DM for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.


  1. Inoue, R.; et al. The feasibility and applicability of stem cell therapy for the cure of type 1 diabetes. Cells. 2021, 10(7), 1589.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.